Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Nasopharyngeal Carcinoma 7Breast Neoplasms 6Esophageal Neoplasms 4Colorectal Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Liver Neoplasms 3Neoplasm Metastasis 2Locally Advanced Rectal Cancer 2Carcinoma, Non-Small-Cell Lung 2Adrenocortical Carcinoma 2Unresectable Gallbladder Cancer 1Turcot syndrome 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Non Squamous Non Small Cell Lung Cancer 1Nasopharyngeal Neoplasms 1Multiple Primary Lung Cancer 1Melanoma 1Locally Advanced or Metastatic Solid Tumors 1Liver Diseases 1Leukemia, Myeloid, Acute 1Her-2 Negative Breast Cancer 1

Interventions

camrelizumab 1Surgical Procedures, Operative 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Endometrioid Endometrial Cancer × camrelizumab × Clear all
NCT06561308 2025-12-01

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Women's Hospital School Of Medicine Zhejiang University

Phase 2 Recruiting
39 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡